Sialic Acid and Aging: Why This Sugar at the Tip of Your Glycans Matters for Inflammation

Sialic acid is a sugar molecule that sits at the outermost tip of glycans (complex sugar chains) attached to Immunoglobulin G (IgG, the most abundant antibody in human blood), and its presence or absence directly determines whether your immune system behaves in an anti-inflammatory or pro-inflammatory way. As we age, the proportion of IgG glycans carrying sialic acid declines, shifting the immune system toward chronic, low-grade inflammation, a process researchers call inflammaging. Measuring sialic acid levels on IgG glycans is therefore one of the most direct windows into how fast your immune system is biologically aging.

For a broader understanding of how glycans work as biological age biomarkers, see our guide Glycans: The Sugars That Reveal Your Biological Age and Immune Health.

What exactly is sialic acid, and what does it do in the body?

Sialic acid is a terminal sugar residue, meaning it occupies the outermost position on glycan chains, and on IgG antibodies it acts as a molecular switch that suppresses inflammatory signaling. When sialic acid is present on an IgG glycan, that glycan directs the immune system toward an anti-inflammatory response; when it is absent, the same IgG molecule can activate pro-inflammatory pathways instead. The process by which sialic acid is added to a glycan chain is called sialylation, and the degree of sialylation across your IgG glycome is a measurable indicator of your current inflammatory burden.

"Glycans on IgG are not only biomarkers that tell you what is going on — they are actually functional effectors that contribute to the progression of low-grade chronic inflammation."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

How does sialylation change as we age?

Sialylation of IgG glycans decreases predictably with age, contributing to the progressive shift from an anti-inflammatory to a pro-inflammatory immune profile that characterizes biological aging. GlycanAge measures 29 distinct glycan structures on IgG, and the pattern of declining sialylation, alongside rising agalactosylation (the absence of galactose sugars, which makes glycans shorter and more pro-inflammatory), is consistent across multiple large population cohorts. This predictable trajectory is what makes sialylation a reliable component of the glycan clock, first published in 2013.

What is the Glycan Shield index, and how does sialic acid relate to it?

The Glycan Shield index represents IgG glycan structures that carry sialic acid and functions as the primary anti-inflammatory index within the GlycanAge report. A higher Glycan Shield score is associated with lower chronic inflammation, healthier immune aging, and stronger immune regulation; the index declines in abundance with advancing biological age. When your GlycanAge result shows a depressed Glycan Shield, it indicates that sialylation of your IgG is reduced. This is a measurable signal that your immune system is operating in a more pro-inflammatory state than is optimal for your chronological age.

Is sialic acid connected to specific diseases, not just general aging?

Reduced sialylation of IgG glycans is associated with a range of chronic conditions, including autoimmune disorders, cardiovascular disease, metabolic syndromes, and neurodegenerative conditions. Critically, these glycan changes occur prior to the onset of disease, sometimes up to 10 years before an official diagnosis, which is what makes sialylation a meaningful early-warning signal rather than a retrospective marker. Research published in Circulation has also examined the role of sialic acid precursors in the relationship between obesity and hypertension, suggesting that sialic acid metabolism sits upstream of several cardiometabolic risk pathways.

How is inflammaging different from ordinary inflammation, and where does sialic acid fit?

Inflammaging is the accumulation of low-grade, chronic, systemic inflammation that builds with age, distinct from the acute inflammation triggered by infection or injury, which resolves once the threat is cleared. Conventional inflammatory markers such as hsCRP, TNF-alpha, and IL-6 reflect acute immune activation rather than the chronic, structural shift in immune biology that drives biological aging, and because they fluctuate with acute events, they cannot reliably distinguish a true inflammatory burden from a transient response. Sialylation of IgG glycans, by contrast, reflects the sustained inflammatory tone of the immune system, making it a more stable and biologically meaningful measure of inflammaging than standard blood panel markers.

Can sialylation levels actually be improved through lifestyle or medical interventions?

"By looking at your GlycanAge, we can see how much of the protective glycans you have already lost and how much of the pro-inflammatory ones you have gained. But this is not fixed — it is not unchangeable. By changing your lifestyle, you can actually improve your glycans."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

Glycan sialylation is modifiable. It responds to lifestyle changes and pharmacotherapy, and those changes are detectable within 3 to 6 months of starting an intervention. Prof. Gordan Lauc, CSO and co-founder of GlycanAge, has described the glycan system as a functional driver of inflammation that can be shifted by both lifestyle change and pharmacotherapy. This responsiveness is what distinguishes glycan-based biological age measurement from static genetic readouts: sialylation reflects your current inflammatory biology, not your inherited predisposition, and it moves when your biology moves.

How does GlycanAge measure sialic acid, and what does the result tell me?

GlycanAge analyses IgG glycans from a simple finger-prick blood sample, extracting and quantifying the full IgG glycome including sialylated structures. The resulting report groups these structures into glycan indexes, including the Glycan Shield, which directly reflects sialylation, and calculates a biological age based on the ratio of pro-inflammatory to anti-inflammatory glycans. A result interpretation call with a longevity specialist then translates your sialylation profile into a personalised picture of where chronic inflammation is driving accelerated biological aging and which interventions are most likely to shift it.

Should I retest after making changes, and how long should I wait?

Retesting after 3 to 6 months of a targeted intervention is the standard recommendation, because that is the window in which meaningful changes in IgG glycosylation, including sialylation, become detectable. The average biological age reduction across GlycanAge repeat testers is 6 years, which reflects the genuine biological responsiveness of the glycan system to sustained lifestyle and medical interventions.

"What I love about the GlycanAge test is that you can see changes within three months, and the results are quite stable. The changes occur quickly — you can see them, monitor what you are doing, and adjust your protocol if needed."

— Dr. Joseph Raffaele, MD, Raffaele Medical, New York

Because glycan measurements are stable in the absence of biological change, a shift in your Glycan Shield index between tests represents a real change in your inflammatory biology, not measurement noise.

If you are ready to measure your sialic acid profile and see where chronic inflammation is driving your biological age, order a GlycanAge test kit and book your 1:1 result Interpretation call with a longevity specialist. Your Glycan Shield index and full glycan report will be ready within 2–3 weeks of returning your sample.

Order your GlycanAge test kit →

External Sources

• https://pubmed.ncbi.nlm.nih.gov/24325898/ — Krištić J, Vučković F, Menni C, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci. 2014;69(7):779–789.

• https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.043490 — Peng J, Vongpatanasin W, Sacharidou A, et al. Supplementation with the sialic acid precursor N-acetyl-D-mannosamine breaks the link between obesity and hypertension. Circulation. 2019;140(24):2005–2018.

• https://pubmed.ncbi.nlm.nih.gov/30046148/ — Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–590.